(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of -5.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Theravance Biopharma's revenue in 2026 is $109,775,000.On average, 8 Wall Street analysts forecast TBPH's revenue for 2026 to be $5,456,370,049, with the lowest TBPH revenue forecast at $3,910,914,065, and the highest TBPH revenue forecast at $9,879,102,348. On average, 8 Wall Street analysts forecast TBPH's revenue for 2027 to be $5,152,310,426, with the lowest TBPH revenue forecast at $3,981,644,788, and the highest TBPH revenue forecast at $7,903,075,667.
In 2028, TBPH is forecast to generate $4,767,776,561 in revenue, with the lowest revenue forecast at $4,106,403,060 and the highest revenue forecast at $5,196,542,904.